NeuroPace Inc unveils early Nautilus study data at ASSFN breakfast symposium

NeuroPace Inc unveils early Nautilus study data at ASSFN breakfast symposium
NeuroPace Inc details Nautilus study

NeuroPace Inc announced plans to present new findings on responsive thalamic neuromodulation during a breakfast symposium at the ASSFN meeting.

The session, scheduled for Monday, June 1 at 7 AM, will feature discussions on 18-month Nautilus study results and updates on a feasibility study for Lennox-Gastaut Syndrome (LGS), with leading researchers Drs. Rolston, Richardson, and Morrell. Attendance is limited and advance reservation is required for the event.

NeuroPace previously invited ASSFN fellows to an exclusive networking dinner focused on neuromodulation practice growth after fellowship, with attendance limited to 30 seats, according to a recent announcement. The company also published a study in Green Journal revealing long-term benefits of its RNS System for drug-resistant epilepsy patients, as detailed in a previous report. These activities highlight NeuroPace’s ongoing engagement with the clinical neuromodulation community.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.